Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 7,000 common shares at $0.69 each. With this transaction, Cerrone's overall interest in Tiziana remains significant at 37.70%. Tiziana focuses on innovative drug delivery technologies for immunotherapies, including its lead candidates: intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor. These candidates are showing favorable safety profiles and responses in clinical studies.

Tiziana Life Sciences (Nasdaq: TLSA) has completed enrollment of the first patient cohort (n=4) in its Expanded Access Program for foralumab, a treatment for non-active Secondary Progressive Multiple Sclerosis (SPMS). Conducted at Brigham and Women’s Hospital, the program assesses two dosing levels: 50 mcg and 100 mcg. This initiative follows positive feedback from investigators and aims to validate the clinical benefits of foralumab, with results from initial PET scans expected soon, potentially paving the way for Phase 2 studies in the coming year.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the enrollment of its first patient cohort in an Expanded Access Program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis (SPMS) patients. This program includes two cohorts of four patients each, testing standard and higher dosing of foralumab. Conducted at Brigham and Women’s Hospital, the study aims to assess the clinical benefits of intranasal foralumab, with PET scans for initial patients scheduled in the coming months, supporting a Phase 2 study expected to begin in mid-to-late 2023.

Tiziana Life Sciences Ltd (NASDAQ: TLSA) will participate in The ThinkEquity Conference on October 26, 2022, at The Mandarin Oriental Hotel, New York. Dr. Matthew W. Davis will present at 2:30 p.m. ET, with live streaming available. Tiziana is focused on innovative immunomodulation therapies through alternative drug delivery methods like nasal and oral routes. Their leading candidates, intranasal foralumab and milciclib, have shown favorable clinical responses. This conference will connect industry insiders and investors, featuring presentations and discussions across various sectors.

Tiziana Life Sciences (Nasdaq: TLSA) announced plans to submit an Investigational New Drug Application (IND) for a Phase 1 trial of intranasal foralumab targeting Alzheimer's disease after receiving feedback from the FDA. The IND is expected to be filed in Q3 2023, pending toxicology study completions, with the trial commencing by year-end. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in treating CNS-related inflammatory diseases. The company aims to explore its efficacy in other conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

Tiziana Life Sciences (Nasdaq: TLSA) presented poster exhibits on intranasal foralumab for treating Progressive Multiple Sclerosis (MS) at the "Preserving the Brain" conference in Milan, Italy. The presentation included results from animal models, healthy subjects, and patients with Progressive MS. Dr. Howard L. Weiner interviewed the first patient treated with intranasal foralumab during the event. Gabriele Cerrone, Executive Chairman, expressed excitement over the recognition of this therapy. The conference aims to advance discussions on neurodegenerative diseases and will run until October 10, 2022.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced positive developments regarding its intranasal foralumab treatment for non-active secondary progressive multiple sclerosis (SPMS). The second Expanded Access patient (EA2) exhibited improved walking ability, requiring no cane for 100 meters, and showed a clinically significant 0.5 point decrease on the Expanded Disability Status Scale (EDSS). These results will be further evaluated with PET imaging to assess microglial activation in Q4 2022. The company plans to enroll four additional patients at Brigham and Women’s Hospital during the same period.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, purchased 29,318 common shares at prices between $0.78 and $0.81, increasing Cerrone's stake from 37.70% to 37.72%. The company focuses on developing innovative drug delivery technologies for immunotherapies, with two lead candidates showing favorable safety and efficacy in clinical studies. Tiziana aims to enhance immunotherapy efficacy through alternative delivery methods such as nasal and oral routes.

Tiziana Life Sciences (Nasdaq: TLSA) has received a prestigious grant from the ALS Association for research on an intranasal anti-CD3 monoclonal antibody aimed at combating Amyotrophic Lateral Sclerosis (ALS) at Brigham and Women’s Hospital. The grant will facilitate studies on dampening microglial activation linked to ALS progression. Tiziana's foralumab, the first entirely human anti-CD3 monoclonal antibody, shows promise in treating various neuroinflammatory conditions including ALS and Alzheimer’s Disease. The company emphasizes the significant unmet need for effective ALS therapies.